Preserving Sight in an Ageing World
Structured abstract
Background. Age-related macular degeneration (AMD) is a leading cause of irreversible central visual loss in older adults. Population ageing raises demand at every stage of care at once: prevention, diagnosis, intravitreal therapy, imaging, rehabilitation and long-term follow-up. The consequences reach beyond visual acuity to reading, mobility, independence, mental health and the capacity of eye-care services.
Methods. A selective, evidence-informed narrative synthesis of professional guidelines, randomised trials, peer-reviewed observational studies, regulatory and reimbursement records, global eye-health sources and, for emerging programmes, labelled company and conference disclosures, with an evidence cutoff of 23 October 2026. Every pipeline statement is dated and labelled by evidence type. Author-proposed concepts are distinguished from established standards.
Findings. Intravitreal anti-VEGF therapy prevents moderate visual loss in most eyes with active neovascular AMD (nAMD) when it is started promptly and sustained; in MARINA, 94.6% of ranibizumab-treated eyes lost fewer than 15 letters at 12 months, compared with 62.2% with sham. Treat-and-extend dosing guided by optical coherence tomography (OCT) is the preferred retreatment strategy in European guidance and matched monthly dosing in randomised comparison, yet real-world cohorts receive fewer injections and keep smaller gains. In geographic atrophy (GA), pegcetacoplan and avacincaptad pegol reduced lesion growth by about 14–22% relative to sham over 24 months; neither programme demonstrated benefit on its prespecified functional endpoints, and both increased new exudative AMD. AREDS-type supplementation reduces progression in eligible intermediate or unilateral advanced disease (AREDS: odds ratio 0.66), not in early or absent AMD. By October 2026, sustained-delivery, combination and gene-therapy programmes had produced both positive and negative pivotal results, and a phase 3 GA trial with a visual-function primary endpoint was approaching its first readout. Artificial intelligence (AI) and home OCT have shown technical accuracy and feasibility, but no published randomised evidence was identified that they improve visual outcomes.
Interpretation. The author’s Sustainable Vision Care Framework organises AMD care as four care-pathway functions and two enabling capacities resting on two cross-cutting foundations. Its most distinctive components are a Structure–Function evidence ladder for judging claimed benefit and a reproducible staff-group capacity model. The framework has not been externally validated; evaluation criteria are proposed.
Conclusion. Sustainable AMD care depends as much on timely pathways, workforce capacity, financing, equity and rehabilitation as on new agents and devices. Anatomical efficacy, patient-valued function and health-system feasibility need to be judged separately and then together.
Keywords: age-related macular degeneration; neovascular AMD; geographic atrophy; anti-VEGF; complement inhibition; retinal imaging; healthy ageing; artificial intelligence; health systems; sustainable vision care.
What is new in the second edition
- Guidelines: the EURETINA nAMD guideline of 12 October 2026, which names treat-and-extend as the preferred retreatment strategy.
- Neovascular AMD: randomised evidence for treat-and-extend and fluid tolerance; real-world and seven-year outcomes; the EU authorisation of the Susvimo implant (September 2026); DAYBREAK, SOL-1 and Duravyu results; the failure of sozinibercept; aflibercept 8 mg label status; and US biosimilar launches.
- Geographic atrophy: the randomised lineage from lampalizumab to GATHER2 two-year results; a two-year real-world series; a dated decisions atlas covering the United States, European Union, United Kingdom, Australia, Japan and China; and the CE marking of the PRIMA retinal implant (July 2026).
- Safety: the European review linking ranibizumab to retinal vasculitis (June 2026) and product-specific complement-inhibitor risks.
- Analytical tools: a revised Structure–Function evidence ladder, a reproducible capacity model and framework indicators with numerators and denominators.
Key points for different readers
- Patients and families: new distortion, a grey patch in central vision or a sudden change in sight needs prompt professional assessment. Severe pain, redness or worsening vision after an eye injection needs urgent care. Supplements and treatments depend on the stage of disease, not on age alone. [1–3]
- Retina clinicians: stage disease with multimodal imaging, treat active nAMD promptly with OCT-led retreatment, and record treatment burden and retention as carefully as short-term response. [1, 2, 4]
- Clinicians and payers considering GA therapy: complement inhibitors slow lesion growth, but neither pivotal programme showed statistically significant benefit on prespecified functional outcomes. Product-specific risks and national reimbursement decisions remain central. [5–8]
- Health-service leaders: measure referral-to-treatment intervals, overdue injections, OCT and room capacity, costs and rehabilitation access, not injection counts alone.
- Researchers and digital-health leaders: separate external validation from demonstrated clinical utility, and test proposed models prospectively.
Plain-language summary for patients and families
AMD affects the macula, the small central part of the retina used for reading, recognising faces and seeing detail. It rarely causes complete blindness, because side vision usually remains. Many people live with early or intermediate AMD for years. Some develop advanced disease of one of two kinds: geographic atrophy, a slow loss of central retinal cells, or neovascular (“wet”) AMD, in which abnormal blood vessels leak or bleed. The two kinds are managed differently and have different urgency.
If straight lines suddenly look bent, a blurred or grey patch appears in central vision, or sight changes unexpectedly, seek prompt advice from an eye-care professional or macula service; do not wait for a routine appointment. If you have recently had an eye injection and develop severe pain, marked redness or worsening vision, seek urgent ophthalmic care. [2]
For active wet AMD, injections that block vascular endothelial growth factor (VEGF) can preserve sight and often improve it. Treatment usually needs repeated appointments and scans, and stopping or stretching treatment without specialist review risks the disease becoming active again. Treatments for geographic atrophy are different: medicines authorised in some countries slow the growth of damaged areas but have not been shown to restore lost vision or to protect everyday function. Their availability differs widely between countries.
Stopping smoking matters. A healthy, Mediterranean-style diet is sensible, but it has not been proven to reverse AMD. AREDS2 supplements can lower the risk of progression in people with intermediate AMD or advanced AMD in one eye; they do not prevent AMD in people without it and do not restore sight already lost. Ask your ophthalmologist or optometrist whether the formulation suits you. [3, 9]
Low-vision aids, accessible reading technology, rehabilitation, emotional support and practical adaptations can improve daily life even when treatment cannot recover vision. If you see things that are not there while remaining otherwise well, tell your clinician: Charles Bonnet syndrome is a recognised, non-psychiatric consequence of sight loss. [2, 10]
1. Scope, questions and methods
AMD is both a retinal disease and a long-term care-delivery problem. This synthesis addresses five linked questions: how burden and severity are counted; which interventions work at which stage; what retinal anatomy reveals, and fails to reveal, about everyday function; how workforce, equipment and financing shape access; and how a disease-specific implementation model could be evaluated.
Search and sources. PubMed/MEDLINE records; professional guidance (American Academy of Ophthalmology, EURETINA, NICE); WHO and Lancet Global Eye Health publications; US Food and Drug Administration (FDA) and DailyMed labels and device decisions; European Medicines Agency (EMA) assessment and withdrawal records; Australian Therapeutic Goods Administration (TGA) and Pharmaceutical Benefits Advisory Committee (PBAC) documents; company filings and releases for pipeline status; and conference reports where no publication existed. Search terms combined age-related macular degeneration, neovascular, geographic atrophy, OCT, anti-VEGF, complement, treat-and-extend, functional outcomes, microperimetry, workforce, health economics, rehabilitation and named products and trials. The first edition’s reference library (March–July 2026) was re-checked and extended to an evidence cutoff of 23 October 2026.
Selection. Purposive and relevance-based. No exhaustive multi-database search, dual screening, formal risk-of-bias scoring or meta-analysis was performed, so the article does not claim systematic-review methods.
Source hierarchy. Regulator records and labels establish authorised indications, dosing and safety language; guidelines establish professional pathways; randomised trials establish comparative efficacy under trial conditions; observational cohorts inform durability, safety and generalisability, with greater confounding; company and meeting disclosures describe emerging programmes and are labelled as such. Cross-trial differences are described, never treated as head-to-head comparisons.
Four dimensions of confidence. Factual verification: whether a date, design or label matches its primary record. Evidence certainty: the strength of findings for a named outcome. Recommendation strength: an editorial judgement integrating benefit, harm, preference and feasibility (not a formal GRADE process). Forecast confidence: kept separate; no probability is assigned to future trial results.
2. Population burden, denominators and healthy ageing
A 2014 pooled analysis projected about 196 million people with AMD of any stage in 2020 and 288 million by 2040. These are all-stage prevalence projections, not counts of people with impaired vision. The Global Burden of Disease (GBD) 2021 analysis estimated 8.06 million people with blindness or vision impairment attributable to AMD in 2021 (95% uncertainty interval 6.71–9.82 million), projected to reach about 21.34 million by 2050. The two figures measure different outcomes with different methods and cannot be placed on one trend line. [11, 12]
GBD analyses also separate rising absolute burden from age-standardised rates that may be stable or falling: ageing and population growth increase the number of people affected even where age-specific risk declines. Tobacco accounted for about 9.96% of age-standardised AMD-attributable vision-impairment burden in 2021, which makes smoking cessation a directly actionable population-level prevention target; a population-attributable fraction does not mean that an individual’s risk falls to baseline when they stop. [12]
Service demand follows a third quantity: the incidence of nAMD and the number of people retained on treatment. Published estimates of either are scarce for most regions, including the Middle East, so prevalence projections alone cannot be used to plan injection clinics.
| Quantity | Estimate (population, period) | What it measures, and what it does not |
|---|---|---|
| Any-stage AMD | 196 million (2020); 288 million (2040), projected [11] | People with any clinical stage; not visual impairment |
| AMD-attributable vision impairment | 8.06 million in 2021 (UI 6.71–9.82); 21.34 million in 2050, projected [12] | Impairment attributed to AMD under the GBD case definition; not everyone with AMD |
| Early and late AMD | Pooled prevalence, ages 45–85: early 8.0%, late 0.4%, any 8.7% [11] | Stage-specific prevalence depends on grading system and age base [13] |
| Geographic atrophy | Varies with age, ancestry and imaging method | Cannot be inferred from trial samples or all-stage prevalence |
| People on active nAMD treatment | Depends on incidence, referral capture, survival and retention | A service-planning stock, not population prevalence |
The Longevity–Vision Paradox, introduced in the first edition of this article (June 2026), names a familiar demographic tension: longer lives add years in which age-related retinal disease can develop, even as treatment improves. It restates, for one disease, the long-standing debate over whether longer lives expand the years lived with chronic disease (Gruenberg’s “failures of success”) or compress them (Fries), and it is offered as an explanatory lens rather than a new causal claim. [14, 15]
WHO defines healthy ageing in terms of functional ability rather than the absence of disease. Central vision supports reading, mobility, self-management, social connection and medication safety, so the outcome that matters extends beyond an OCT metric to what a person can do. Associations between visual impairment and falls or depression do not show that any single retinal intervention prevents those outcomes. [16–19]
3. Pathobiology, risk factors and genetics
AMD arises from interacting processes: age-related retinal pigment epithelium (RPE) dysfunction, photoreceptor and choriocapillaris injury, lipid-rich drusen and subretinal drusenoid deposits, oxidative and mitochondrial stress, dysregulated complement and innate immunity, and genetic susceptibility. Different mechanisms may dominate at different stages. Complement involvement makes complement inhibition biologically plausible in GA; it does not by itself establish a functional benefit. [1]
Age is the strongest risk factor and smoking the strongest modifiable one. Variants at CFH and ARMS2/HTRA1 account for much of the inherited risk at population level, but routine genetic testing is not recommended for ordinary AMD management, and genotype-directed choice of supplement is not supported. Hypertension, adiposity, diet and cardiovascular risk are associated with AMD in some datasets; conclusions about causation and modifiability should be proportionate to that evidence. [1, 2]
Clinical risk stratification. The AREDS simplified severity scale assigns one point per eye for large drusen and one for pigmentary abnormalities (with one point for bilateral medium drusen when neither eye has large drusen). Across 0, 1, 2, 3 and 4 points, the five-year risk of advanced AMD in at least one eye is about 0.5%, 3%, 12%, 25% and 50%. The scale remains a practical, widely used counselling tool. [20]
OCT adds prognostic information beyond colour photography. Subretinal drusenoid deposits, intraretinal hyperreflective foci, high or rising drusen volume, OCT hypertransmission and the earliest atrophic changes (incomplete RPE and outer retinal atrophy, including nascent GA) mark eyes at higher risk. Several of these are validated as risk markers but not yet as decision thresholds. [21, 22]
4. Classification, phenotypes and imaging
4.1 Stage definitions
The Beckman clinical classification distinguishes no apparent ageing changes, normal ageing changes (drupelets ≤63 µm only), early AMD (medium drusen >63 and ≤125 µm), intermediate AMD (large drusen >125 µm and/or AMD pigmentary abnormalities) and late AMD (neovascular AMD and/or GA). Pigmentary abnormalities count towards AMD only when accompanied by at least medium drusen. Staging should follow these thresholds rather than a simple “dry versus wet” division. [13]
The Classification of Atrophy Meetings (CAM) define atrophy on OCT. Complete RPE and outer retinal atrophy (cRORA) requires a zone of choroidal hypertransmission of at least 250 µm with corresponding RPE attenuation or disruption, evidence of overlying photoreceptor degeneration, and no scrolled RPE or other signs of an RPE tear. Incomplete RPE and outer retinal atrophy (iRORA) describes earlier changes that do not meet these thresholds. [21, 22]
Neovascular AMD is best described with the CONAN nomenclature for macular neovascularisation (MNV): type 1 beneath the RPE, type 2 above it in the subretinal space, and type 3 arising within the retina. Polypoidal choroidal vasculopathy (PCV), a subtype of type 1 MNV with aneurysmal or polypoidal lesions, is over-represented among people of Asian ancestry with nAMD and changes both diagnosis and treatment choice. [23, 24]
| Category | Working definition | Clinical implication |
|---|---|---|
| No apparent AMD / normal ageing | No drusen, or drupelets ≤63 µm only, without AMD pigmentary change [13] | Routine eye care; smoking advice |
| Early AMD | Medium drusen (>63 to ≤125 µm), no AMD pigmentary abnormality [13] | Risk counselling; AREDS2 not indicated |
| Intermediate AMD | Large drusen (>125 µm) and/or AMD pigmentary abnormality, no late disease [13] | AREDS2 eligibility; self-monitoring; OCT risk features [3] |
| cRORA | Hypertransmission ≥250 µm with RPE attenuation, photoreceptor degeneration, no RPE tear [21] | Defines atrophy on OCT; GA when it meets clinical criteria |
| iRORA | Earlier atrophic change not meeting cRORA thresholds [22] | High-risk precursor; research endpoint |
| Neovascular AMD | Type 1, 2 or 3 MNV, including PCV [23] | Urgent assessment and anti-VEGF treatment |
4.2 Imaging: roles and limits
- Structural OCT is central to staging, to detecting intraretinal and subretinal fluid and to monitoring nAMD activity.
- Colour fundus photography documents drusen and pigment and underpins the Beckman and AREDS grading systems.
- Fundus autofluorescence delineates atrophy and its growth and complements OCT in GA trials.
- Fluorescein angiography clarifies suspected neovascularisation when OCT is equivocal.
- OCT angiography shows flow non-invasively but can miss activity and is prone to segmentation artefact.
- Indocyanine green angiography (ICGA) is the reference investigation for PCV when its recognition would change treatment. [1, 2, 4, 25]
No single modality is infallible, and each test should answer a clinical question rather than be repeated by default. Routine OCT of everyone over a given age is not an established population-screening recommendation; assessment follows symptoms, examination and individual risk. [1, 2]
The clinical context for newer image-analysis tools is examined further in AI-Powered Retinal Imaging: OCT Innovation and Precision Eye Care, with emphasis on validation and the limits of automation.
4.3 PCV and differential diagnosis
In trial settings, PCV was diagnosed on ICGA by early focal subretinal hyperfluorescence with at least one supporting feature, such as a nodular appearance, a hypofluorescent halo or pulsatile filling. Where ICGA is unavailable, the Asia-Pacific Ocular Imaging Society PCV Workgroup proposed three major OCT criteria: a sub-RPE ring-like lesion, complex RPE elevation on en face OCT and a sharp-peaked pigment epithelial detachment. Together they discriminated PCV from typical nAMD with an area under the curve of 0.90. The workgroup also recommended the terms “polypoidal lesion” and “branching neovascular network”. [24–26]
Central serous chorioretinopathy, pachychoroid neovasculopathy, myopic MNV, inflammatory choroidal neovascularisation, vitelliform lesions and pattern or other macular dystrophies can mimic AMD. An apparently “refractory” case deserves reconsideration of the diagnosis, the lesion type, adherence and image quality before injections are escalated. Because phenotype frequencies differ between populations, an image-based algorithm trained in one population should not be assumed safe in another without local validation. [23, 24]
5. Prevention, AREDS2, counselling and surveillance
No tablet, diet or screening programme has been shown to prevent AMD in the general population. Smoking cessation, cardiovascular risk management and a healthy dietary pattern are reasonable for everyone. A Mediterranean-type diet is associated with slower progression in observational cohorts, including analyses reviewed by Keenan and colleagues in 2026, but no randomised trial has shown that a prescribed diet modifies the disease. [9]
The right action depends on symptoms and diagnosed disease, not on age alone.
Routine eye examination
AREDS2 not indicated
Review OCT risk features
Do not wait for routine follow-up
Treat-and-extend · fellow-eye checks
Low-vision rehabilitation and support
Eligibility and follow-up intervals depend on clinical assessment and local guidance.
Supplementation: what the trials showed.
- AREDS: in participants with intermediate AMD or advanced AMD in one eye, antioxidants plus zinc reduced progression to advanced AMD over about five years (odds ratio 0.66, 99% CI 0.47–0.91). The National Eye Institute summarises this as a reduction in risk of about one quarter. Participants with no or early AMD did not benefit. [3, 27]
- AREDS2: adding lutein/zeaxanthin or omega-3 fatty acids gave no overall additional benefit. Lutein and zeaxanthin replaced beta-carotene, which had raised lung-cancer risk in smokers, and a lower zinc dose (25 mg) performed similarly to 80 mg. [28]
- Ten-year follow-on: lutein/zeaxanthin was associated with lower risk of progression to late AMD than beta-carotene (hazard ratio 0.85, 95% CI 0.73–0.98), and beta-carotene was associated with nearly double the risk of lung cancer (odds ratio 1.82, 95% CI 1.06–3.12). These analyses were post hoc. [29]
The standard AREDS2 formulation contains vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (as zinc oxide) and copper 2 mg (as cupric oxide). It is appropriate for intermediate AMD in one or both eyes, or late AMD in one eye. It has no established benefit in early AMD or in people without AMD, and probably little benefit once late AMD affects both eyes. Current and former smokers should avoid beta-carotene-containing formulations. [1, 3, 28]
Interventions that did not work. Prophylactic subthreshold nanosecond laser in intermediate AMD did not slow progression to late AMD overall in the LEAD trial. A post hoc subgroup without reticular pseudodrusen appeared to benefit, while eyes with reticular pseudodrusen appeared to progress faster, so the treatment is not recommended outside trials. [30]
The wider health-system consequences of missed opportunities for early intervention are developed in The Prevention Liability: The Hidden Balance Sheet of Delayed Care; that conceptual analysis is complementary to, rather than evidence for, any particular AMD prevention strategy.
Self-monitoring. Patients can watch for distorted lines, reading changes and Amsler-grid changes, but a normal Amsler result does not exclude active disease. Home hyperacuity testing and home OCT can add information for selected diagnosed patients within a clinical service; neither replaces prompt assessment when symptoms change. [2, 31, 32] Monitoring the fellow eye is particularly important after nAMD in one eye, because the fellow eye is at increased risk. [1]
| Stage | High-value discussion | Clinical boundary |
|---|---|---|
| No diagnosed AMD | Stop smoking; healthy diet; routine eye examination | OCT is not a population screening test triggered by age alone |
| Early AMD | Smoking cessation; risk counselling; examination according to findings | AREDS2 has no established preventive benefit at this stage [3] |
| Intermediate AMD, or late AMD in one eye | AREDS2 after reviewing eligibility, formulation, interactions and preferences; self-monitoring | A supplement reduces risk; it does not cure or restore vision [27, 28] |
| Suspected new nAMD | Urgent macula assessment for new distortion, blur or scotoma | Home charts do not replace examination and imaging [2] |
| Treated nAMD | Adherence; injection and imaging schedule; fellow-eye advice | Longer intervals need clinician-led activity assessment [4] |
| GA or established visual loss | Function; access to authorised therapy; rehabilitation and low-vision planning | Slowing growth is not restoration of lost vision [5, 6, 10] |
6. Neovascular AMD: diagnosis, evidence and treatment strategy
6.1 Why timely treatment matters
Intravitreal VEGF inhibition transformed nAMD from a disease that usually caused progressive, severe central visual loss into one in which most treated eyes keep useful vision. In MARINA, 94.6% of eyes receiving monthly ranibizumab 0.5 mg lost fewer than 15 letters at 12 months, against 62.2% with sham injection. In ANCHOR, the corresponding figures were 94.3% (0.3 mg) and 96.4% (0.5 mg) against 64.3% with verteporfin photodynamic therapy, with mean gains of 8.5 and 11.3 letters against a loss of 9.5 letters. [33, 34]
Outcomes depend on how early treatment begins. NICE recommends referral of suspected active nAMD to a macula service within one working day and, where treatment is indicated, starting it as soon as possible and within 14 days of referral. These are UK benchmarks, not universal statutory standards. Specialist examination and OCT confirm activity; fluorescein angiography is used when examination and OCT do not settle the question. [2]
6.2 Agents and the strength of evidence
Ranibizumab, aflibercept, bevacizumab, brolucizumab and faricimab each have randomised evidence in nAMD; they differ in licensing, dosing, cost and safety profile.
- Bevacizumab matched ranibizumab on mean visual acuity in CATT and IVAN under comparable regimens. CATT reported more systemic serious adverse events with bevacizumab, without a consistent pattern that established causation. [35–37]
- Aflibercept 2 mg every 8 weeks after loading was non-inferior to monthly ranibizumab in VIEW 1 and 2. [38]
- Faricimab (dual VEGF-A and angiopoietin-2 inhibition) was non-inferior to aflibercept 2 mg in TENAYA and LUCERNE, with protocol-defined extension to 16 weeks in eligible participants. [39]
- Aflibercept 8 mg was non-inferior to aflibercept 2 mg in PULSAR at 48 weeks with 12- and 16-week intervals. The US label specifies every 8 to 16 weeks after three monthly doses; in April 2025 the FDA declined an application to extend intervals to 24 weeks, while some other regulators allow longer intervals. Local labels should be checked. [40, 41]
- Brolucizumab was non-inferior to aflibercept in HAWK and HARRIER but carries a clinically important risk of intraocular inflammation, retinal vasculitis and retinal vascular occlusion. [42, 43]
These results show the potential for durable treatment. They do not mean that every eye can safely be treated at the longest interval studied.
| Trial | Comparison | Principal result | Limits for practice |
|---|---|---|---|
| MARINA (2006) [33] | Monthly ranibizumab vs sham | 94.6% vs 62.2% lost <15 letters at 12 months | Historical sham control; eligibility differs from today |
| ANCHOR (2006) [34] | Monthly ranibizumab vs verteporfin PDT | 94.3–96.4% vs 64.3% lost <15 letters | Predominantly classic lesions |
| VIEW 1/2 (2012) [38] | Aflibercept 2 mg regimens vs monthly ranibizumab | Non-inferior BCVA at week 52 | Fixed-interval protocol |
| CATT (2011–12) [35, 36] | Bevacizumab vs ranibizumab, monthly or PRN | Similar mean acuity by drug; PRN slightly worse than monthly at 2 years | Systemic safety differences of uncertain cause |
| IVAN (2013) [37] | Bevacizumab vs ranibizumab, continuous or discontinuous | Similar efficacy by drug | UK factorial design |
| HAWK/HARRIER (2020) [42] | Brolucizumab vs aflibercept | Non-inferior BCVA | Inflammation and occlusive vasculitis [43] |
| TENAYA/LUCERNE (2022) [39] | Faricimab up to 16-weekly vs aflibercept 8-weekly | Non-inferior BCVA | 16-week suitability varies by eye |
| PULSAR (2024) [40] | Aflibercept 8 mg 12/16-weekly vs 2 mg 8-weekly | Non-inferior BCVA at week 48 | Interval-adjustment rules matter |
| Archway (2022) [44] | Port Delivery System vs monthly ranibizumab | Non-inferior BCVA | Surgery, refills and device-specific adverse events |
6.3 Loading, treat-and-extend and fluid tolerance
Treatment usually starts with three monthly injections. Fixed-interval dosing maintains control but may impose unnecessary visits on stable eyes. Pro re nata (as-needed) dosing reduces injections but needs frequent assessment and is vulnerable to missed reactivation; under-treatment should not be presented as efficiency. Treat-and-extend keeps every visit an injection visit and lengthens or shortens the interval according to clinical and OCT activity. EURETINA’s 2026 guideline names treat-and-extend as the preferred retreatment strategy and defines activity primarily by changes in retinal fluid on OCT. [4]
Two randomised trials support this approach:
- CANTREAT: in a prespecified 24-month analysis (primary endpoint at 12 months), treat-and-extend ranibizumab gained 6.8 letters against 6.0 with monthly dosing (difference from unrounded means 0.9 letters, 95% CI −1.6 to 3.3; non-inferiority margin −5), with 17.6 against 23.5 injections. [45]
- FLUID: tolerating up to 200 µm of subfoveal subretinal fluid gave visual results non-inferior to treating until completely dry (+2.6 vs +3.0 letters at 24 months), with fewer injections (15.8 vs 17.0). [46]
A useful clinical record captures baseline acuity and imaging, lesion type, the treatment chosen and why, response after loading, OCT fluid and haemorrhage, each interval change and its reason, adverse events, missed visits, visual outcome and the patient’s goals. Large vascularised pigment epithelial detachments carry a risk of RPE tear and need explicit counselling. Falling vision with an apparently dry OCT calls for evaluation of atrophy, fibrosis, cataract and other causes.
6.4 Switching, stopping, and the real-world gap
Before declaring an inadequate response, check the diagnosis, chronic structural damage, adherence, activity criteria, measurement variability and treatment delivery. Switching agent may help selected eyes or allow a more manageable schedule, but it is not a guaranteed rescue. Stopping treatment requires weighing chronic inactivity, irreversible damage, visual potential, burden and recurrence risk with the patient, with a documented monitoring plan. EURETINA and NICE both address review, switching and stopping. [2, 4]
Long-term and real-world data show how much benefit is lost outside trial conditions:
- AURA, a multi-country cohort of 2,227 patients, found a mean gain of 2.4 letters at one year and 0.6 letters at two years, with means of 5.0 and 2.2 injections. [47]
- SEVEN-UP followed 65 patients from ANCHOR and MARINA for a mean of 7.3 years. Mean acuity was 8.6 letters below baseline; 23% of eyes saw 20/40 or better and 37% saw 20/200 or worse. [48]
- CATT five-year follow-up showed that early gains were not sustained on average, with macular atrophy and fibrosis contributing. [49]
Attrition, delayed starts, missed appointments, under-treatment, fibrosis, atrophy and multimorbidity all erode gains. Whether anti-VEGF exposure itself accelerates macular atrophy remains uncertain, because disease severity, treatment intensity and selection of long-term survivors confound the association. This gap between efficacy and delivered benefit is what the article calls the Implementation Chasm (Section 11).
6.5 Durability, delivery devices and the October 2026 pipeline
Longer dosing intervals can reduce travel, injections and clinic congestion. The clinical question is whether vision and safety are maintained against a credible comparator with an adequate monitoring plan; fewer injections are not evidence of visual non-inferiority, and fewer injections are not the same as fewer visits.
- Susvimo (ranibizumab via the Contivue port delivery implant) received EU marketing authorisation on 18 September 2026 for adults with nAMD that is stable after responding to intravitreal anti-VEGF therapy, with refills typically every six months. Implantation and refill carry device-specific risks. In the United States the implant was voluntarily recalled in October 2022 because of septum dislodgement and was reintroduced after FDA approval in 2024. A separate 2023 EU application was withdrawn on 2 May 2023 because Notified Body review of the device was incomplete. [44, 50–52]
- DAYBREAK (Kodiak Sciences; reported 28 September 2026 and presented at the American Academy of Ophthalmology on 9 October 2026): tarcocimab tedromer (Zenkuda) and tabirafusp tedromer each met non-inferiority to aflibercept 2 mg at one year. Reported gains were +7.2 and +6.3 letters against +7.6. Fifty-four per cent of tarcocimab-treated patients reached the six-month maximum interval. Retreatment was decided at monthly assessment visits, so the trial shows reduced injection need, not reduced visit burden. No intraocular inflammation was reported with tarcocimab. Results are not yet peer-reviewed, and a regulatory filing was planned for late 2026. [53, 54]
- SOL-1 (axitinib hydrogel, Axpaxli; sponsor-reported February 2026): 74.1% against 55.8% of patients maintained vision at week 36. Patients received two aflibercept loading doses, and early responders were randomised to one axitinib implant or one aflibercept injection, so the comparison is against a single dose, not continuous on-label aflibercept. [55]
- Duravyu (vorolanib insert; LUGANO and LUCIA): EyePoint reported on 19 October 2026 that both pivotal trials missed their non-inferiority vision endpoints against scheduled aflibercept, despite fewer injections. [56]
- Sozinibercept (anti-VEGF-C/D add-on): the COAST and ShORe phase 3 trials did not meet their primary endpoints in March 2025. In ShORe, combination therapy gained 13.3 and 12.6 letters against 14.3 with ranibizumab alone, and development in nAMD was stopped. [57]
- Gene therapy: subretinal surabgene lomparvovec (ABBV-RGX-314) completed enrolment in two pivotal trials, with topline results expected in the fourth quarter of 2026 and filings in 2027. [58]
| Programme | Mechanism | Status | Evidence type |
|---|---|---|---|
| Susvimo (Archway; EU 2026) | Ranibizumab port delivery implant | EU-authorised for stable, previously responsive nAMD; US-marketed | Peer-reviewed trial; regulator decision [44, 50, 52] |
| Aflibercept 8 mg (PULSAR) | High-dose anti-VEGF | Authorised; US interval 8–16 weeks; 24-week extension declined by FDA (2025) | Peer-reviewed trial; regulator decision [40, 41] |
| Tarcocimab, tabirafusp (DAYBREAK) | Antibody biopolymer conjugate; anti-VEGF/IL-6 | Phase 3 non-inferiority met; filing planned | Sponsor topline; conference [53, 54] |
| Axpaxli (SOL-1) | Axitinib intravitreal hydrogel | Phase 3 superiority over a single-dose comparator | Sponsor (SEC filing) [55] |
| Duravyu (LUGANO, LUCIA) | Vorolanib insert | Non-inferiority not met | Sponsor (SEC filing) [56] |
| Sozinibercept (COAST, ShORe) | VEGF-C/D trap add-on | Primary endpoints not met; discontinued | Sponsor (SEC filing) [57] |
| Surabgene lomparvovec (ATMOSPHERE, ASCENT) | Subretinal AAV anti-VEGF gene therapy | Pivotal readout expected Q4 2026 | Sponsor [58] |
What this means for services. Durability creates value only when preserved vision, adverse events, implant and refill costs, monitoring workload and patient travel are considered together. Registries and post-authorisation surveillance remain essential. Services should track patients retained in effective control rather than injection counts: time to first treatment, median and 90th-centile interval, proportion overdue, OCT activity at each visit, visual change at 12 and 24 months, clinic slots per patient-year, complications and rehabilitation referral.
6.6 Bevacizumab, biosimilars and procurement
Bevacizumab’s status is more varied than the usual “off-label” description. In many settings it is repackaged from an oncology formulation under local governance, which depends on lawful supply and aseptic compounding. The EU has separately authorised an ophthalmic bevacizumab, Lytenava (bevacizumab gamma), for adult nAMD since 27 May 2024. [59]
Ranibizumab and aflibercept biosimilars are authorised in the EU, and several aflibercept biosimilars are approved in the United States; Pavblu launched there in November 2024, followed by Yesafili, designated interchangeable, in August 2026. Approval, interchangeability, formulary policy and patient communication are separate matters that differ by jurisdiction. Biosimilars can lower acquisition cost and strengthen supply, but net savings depend on tender prices, reimbursement rules, handling and whether formulary-driven switching disrupts continuity of care. [60, 61]
6.7 PCV, haemorrhage and treatment selection
PCV deserves a dedicated decision pathway, particularly with submacular or recurrent haemorrhage or a poor response to anti-VEGF therapy.
- EVEREST II: ranibizumab plus verteporfin photodynamic therapy (PDT) gave a mean gain of 9.6 letters at 24 months against 5.5 letters with ranibizumab alone (P = 0.005), with more complete polypoidal regression and fewer ranibizumab injections. [25]
- PLANET: aflibercept monotherapy was non-inferior to aflibercept with rescue PDT, but few patients met rescue criteria, which limits conclusions about adjunctive PDT in refractory eyes. [62]
The two trials are complementary: many eyes respond to anti-VEGF alone, and PDT remains a valuable adjunct for persistent polypoidal activity. Both enrolled mainly Asian patients with ICGA-confirmed disease, which limits extrapolation to settings with different case mix or no ICGA. [24]
Extensive new submacular haemorrhage needs urgent retinal assessment. Management may combine anti-VEGF therapy with pneumatic displacement, with or without tissue plasminogen activator, or vitrectomy, depending on the size, thickness, duration and foveal involvement of the haemorrhage and on local expertise. These approaches are distinct from the PCV-specific comparisons in EVEREST II and PLANET. [1]
7. Geographic atrophy: efficacy, function, safety and regulatory divergence
7.1 Disease and patient-centred outcomes
GA is progressive loss of RPE, photoreceptors and choriocapillaris. Untreated lesions grow by roughly 2 mm² a year on average, with wide variation by lesion size, shape, location and fellow-eye status. Lesions often spare the fovea until late, so visual acuity can remain good while reading, low-light vision and navigation deteriorate. [63]
A square-millimetre difference in growth therefore does not automatically translate into preserved reading speed, face recognition, independence or best-corrected visual acuity (BCVA) for a given patient. Lesion location, foveal involvement, residual photoreceptor function and fellow-eye vision all modify the relationship. The Structure–Function Challenge is this article’s central analytical contribution: when a therapy changes anatomy but its functional benefit is uncertain, patients and health systems need to ask what meaningful benefit can be expected, at what cost and with what risk.
7.2 How the randomised evidence developed
Failure first. Lampalizumab, an antibody fragment against complement factor D, did not reduce GA growth in the CHROMA and SPECTRI phase 3 trials (1,881 patients). Mean growth over 48 weeks was about 2 mm² in every arm, and no subgroup benefited. The trials established the natural-history scale against which later effects are measured and showed that a plausible complement target can fail. [63]
Phase 2 signals. In FILLY, monthly pegcetacoplan (C3 inhibition) reduced lesion growth by 29% at 12 months (P = 0.008); the 20% reduction with every-other-month dosing was not statistically significant (P = 0.067). New exudative AMD occurred in 20.9%, 8.9% and 1.2% of monthly, every-other-month and sham eyes. In GATHER1, avacincaptad pegol (C5 inhibition) reduced square-root-transformed growth by 27.4% (2 mg) and 27.8% (4 mg) at 12 months. [64, 65]
Pivotal trials. In OAKS and DERBY, pegcetacoplan reduced growth at 24 months relative to sham:
- OAKS: 22% monthly (absolute difference −0.90 mm²) and 18% every other month (−0.74 mm²).
- DERBY: 19% monthly (−0.75 mm²) and 16% every other month (−0.63 mm²).
DERBY had missed its original 12-month primary endpoint. Neither trial showed a statistically significant benefit on its prespecified visual-function outcomes at 24 months. [5]
GATHER2’s 12-month primary endpoint was met: square-root-transformed growth of 0.336 mm/year with avacincaptad pegol against 0.392 mm/year with sham (difference 0.056 mm/year, about 14%; P = 0.0064). All treated patients received monthly avacincaptad pegol in year 1; at month 12, those completing the year were re-randomised to monthly (n = 96) or every-other-month (n = 93) dosing. At two years, total growth was 4.46 mm² with continued monthly dosing, 4.20 mm² after switching to every-other-month dosing and 5.18 mm² with sham, about 14% and 19% less; the second comparison was tested only nominally. New macular neovascularisation (reported in the trial as choroidal neovascularisation) reached 11.6% in pooled treated eyes against 9.0% with sham, and the prespecified two-year analysis of persistent loss of 15 or more letters did not show a statistically significant benefit. [6, 66]
Pegcetacoplan’s US label reports pooled-sham reductions of 18–22% (monthly) and 17–18% (every other month), and new neovascular AMD in 12%, 7% and 3% of monthly, every-other-month and sham eyes by month 24. These differ slightly from the per-trial figures above because the comparator is pooled. Avacincaptad pegol’s US label specifies monthly dosing. [7, 8]
| Study | Structural result | Function at the reported time point | Material caution |
|---|---|---|---|
| CHROMA/SPECTRI, 48 weeks [63] | No reduction (growth about 2 mm²/year in all arms) | Not applicable | Defines natural-history scale |
| FILLY, 12 months [64] | −29% monthly (P = 0.008); −20% every other month (not significant) | Not powered for function | Exudative AMD 20.9% / 8.9% / 1.2% |
| GATHER1, 12 months [65] | −27.4% (2 mg); −27.8% (4 mg) | Not powered for function | Phase 2/3 |
| OAKS, 24 months [5] | −22% monthly; −18% every other month | No difference in key functional secondary outcomes | Exudative AMD 11% / 8% / 2% |
| DERBY, 24 months [5] | −19% monthly; −16% every other month | No difference in key functional secondary outcomes | 12-month primary not met; exudative AMD 13% / 6% / 4% |
| GATHER2, 12 and 24 months [6, 66] | −14% (primary, 12 months); at 24 months −14% (monthly throughout) and −19% (monthly, then every other month after re-randomisation; nominal) | Persistent ≥15-letter loss not significantly reduced | New MNV 11.6% vs 9.0%; every-other-month dosing not US-labelled |
| GALE extension, 36 months [67] | Continued reduction under open-label treatment | Not controlled for function | Selection after the trials; no concurrent sham |
| Shen et al., two-year real-world series [68] | 41% slower square-root growth against each eye’s pretreatment rate (49 eyes) | Mean BCVA fell from 63 to 55 letters | Retrospective, uncontrolled; regression effects possible |
7.3 Safety and shared decisions
Repeated injections carry risks of endophthalmitis, retinal detachment, intraocular pressure rise and inflammation. Pegcetacoplan’s US label warns of retinal vasculitis and/or retinal vascular occlusion, which can cause severe visual loss, and of increased conversion to neovascular AMD. The sponsor has reported post-marketing retinal vasculitis at about 1 per 4,000 first injections and far less often after later injections (to December 2025); these are company data on file, not peer-reviewed estimates. [8, 69]
A population-based pharmacovigilance study found a broader range of ocular adverse-event reports for pegcetacoplan than for avacincaptad pegol. Disproportionality analyses of spontaneous reports generate signals; they cannot estimate incidence or compare products fairly. The absence of a vasculitis signal in an avacincaptad pegol trial does not prove zero real-world risk, and pegcetacoplan’s post-marketing rates should not be assumed for avacincaptad pegol. Counselling and monitoring should follow each product’s current national label. [6, 7, 70]
The decision to start GA therapy should document lesion location and growth, fellow-eye prognosis, current function, the expected treatment and monitoring burden, the patient’s capacity to attend, their preferences and the precise state of the evidence. It should not promise restoration of lost vision, and a patient may reasonably decline repeated injections when the expected anatomical gain does not outweigh the burden and uncertainty for them.
7.4 Devices and restorative technology
- Photobiomodulation (Valeda). The FDA granted a De Novo classification in November 2024 for selected patients with dry AMD and BCVA between 20/32 and 20/70. In the sham-controlled LIGHTSITE III trial, treated eyes gained a mean of about 5.4 letters at 13 months, with a statistically significant difference from sham. A 24-month analysis presented at a meeting reported fewer new GA lesions, but this has not yet been peer reviewed. The device’s population and claim differ from those of intravitreal complement inhibitors; it is not a treatment shown to prevent late AMD in the general population. [71, 72]
- PRIMA subretinal implant. This photovoltaic implant, which provides prosthetic central form vision, received European CE marking under the Medical Device Regulation on 22 July 2026. The single-arm PRIMAvera study enrolled 38 people with profound central loss from GA. At 12 months, 26 of 32 assessed participants (81%; 95% CI 64–93%) achieved a clinically meaningful gain in prosthetic visual acuity, and natural peripheral vision was not reduced on average. Twenty-six serious adverse events occurred in 19 participants, mostly after surgery. The implant does not slow atrophy or restore natural vision. CE marking of a device differs from medicinal-product authorisation and does not guarantee reimbursement, and PRIMA had no US marketing authorisation at the cutoff. [73, 74]
7.5 GA programmes awaiting results
- Vonaprument (ARCHER II). This intravitreal complement C1q inhibitor is being tested in a phase 3 GA trial whose primary endpoint is visual function: the proportion of patients with confirmed loss of 15 or more letters at two consecutive visits. In August 2026 a month-24 primary analysis was added to the original month-15 analysis. The trial enrolled 659 patients, and month-15 topline results were expected in the fourth quarter of 2026. No results had been reported at the cutoff. [75, 76]
- Tinlarebant (PHOENIX). This oral visual-cycle modulator is in a 24-month placebo-controlled trial in 530 patients, with lesion growth as the primary endpoint. No efficacy data had been reported. [77]
- Other approaches. Gene, cell, neuroprotective and further complement strategies were at earlier clinical stages at the cutoff.
What this means for services. Anatomical slowing requires repeated injections, OCT and autofluorescence assessment, surveillance for neovascular conversion, and access to counselling and rehabilitation. Health-technology assessment asks what improvement matters to patients, not only whether lesions grow more slowly, so funding cannot be inferred from FDA approval. Pathway models should include patient travel, missed appointments, specialist availability, adverse-event response and planned retreatment, and should recognise that a new GA pathway can displace nAMD capacity in the same clinic (Section 13).
7.6 The Structure–Function evidence ladder
From what is measured to what is lived · status of GA complement-inhibitor evidence, October 2026.
↑ Closer to lived experience
Rungs describe distance from lived experience, not strength of evidence. Each claim should name the rung reached and the evidence used.
Figure 2 places the outcomes an AMD therapy can claim on a ladder ordered by distance from lived experience, from lesion anatomy at the base to independence and participation at the top. The rungs are not a hierarchy of evidentiary strength. BCVA (rung 4) is not a “truer” outcome than microperimetry (rung 3); in extrafoveal GA, where the fovea is spared by definition, BCVA is simply insensitive. Each rung asks a different question, and a claim of benefit should state which rung has been reached by which kind of evidence.
The case for structural endpoints deserves to be stated plainly. Atrophy is irreversible tissue loss. Enlarging atrophy eventually reaches the fovea in many eyes, with loss of central vision. Two-year trials are short and underpowered for slowly changing functional outcomes. The FDA accepted lesion growth as the primary efficacy endpoint for both approved products. [7, 8] On this view, slowing growth is valuable in itself, especially in eyes whose fovea is still intact.
The case for caution is equally clear. Three pivotal trials with about 1,700 participants combined (OAKS, DERBY and GATHER2) did not show prespecified functional benefit at 24 months. Post hoc analyses are vulnerable to multiplicity. Treatment adds burden and new risks, including neovascular conversion and, for pegcetacoplan, retinal vasculitis. This is the general surrogate-endpoint problem, well described in other fields: an intervention can change a biomarker without improving how patients feel, function or survive. [78]
The resolution is empirical. Trials designed with function as the primary endpoint, led by ARCHER II, test the inference directly. Until such trials report, the defensible position is that anatomical efficacy is established, while functional benefit has not been demonstrated in prespecified analyses and post hoc and real-world signals are hypothesis-generating. A matched real-world analysis presented at a July 2026 meeting suggested slower acuity decline with pegcetacoplan, but it has not been peer reviewed and cannot settle the question. [75, 79]
| Evidence | Most secure supported rung | What is still needed above it |
|---|---|---|
| OAKS/DERBY, 24 months [5] | Rung 1: prespecified reduction in lesion growth | Prespecified functional benefit; post hoc analyses are hypothesis-generating |
| GATHER2, 24 months [6] | Rung 1: reduction in lesion growth | Persistent ≥15-letter loss objective not met |
| GALE open-label extension [67] | Rung 1: continued anatomical effect under treatment | A randomised comparator for long-term function |
| Exploratory and post hoc OAKS/DERBY analyses of photoreceptors and microperimetry [5] | Rungs 2–3: supportive local tissue and sensitivity signals | Prespecified replication linked to daily function |
| Shen et al. real-world series [68] | Rung 1: within-eye slowing | An untreated comparator; mean acuity declined |
| ARCHER II (pending) [75] | Designed to test rung 4 directly | Results not reported at the cutoff |
Regulatory interpretation as applied epistemology. The FDA’s authorisations, the European refusal and withdrawal, Australian registration and Australian reimbursement decisions rest on overlapping anatomical evidence but answer different questions: whether the benefit–risk balance justifies marketing; whether a structural outcome is clinically meaningful; how much uncertainty can be accepted; and whether a medicine offers enough value at a given price. Reducing these decisions to a dispute about efficacy, or assuming that agencies applied identical mandates, would mislead. The CHMP’s negative opinion on pegcetacoplan concerned whether the clinical relevance of reduced lesion growth had been established for that application; it was not a general rejection of structural endpoints. [80–82]
7.7 Geographic atrophy decisions atlas, status at 23 October 2026
Marketing authorisation, device conformity assessment, health-technology appraisal, pricing, reimbursement and availability are different decisions. The entries below concern specified territories and indications and are not interchangeable efficacy judgements.
| Jurisdiction | Pegcetacoplan (Syfovre) | Avacincaptad pegol (Izervay) |
|---|---|---|
| United States | FDA-approved 17 February 2023; dosing every 25–60 days; retinal vasculitis and occlusion warning [8] | FDA-approved 4 August 2023; monthly dosing in the February 2026 label [7] |
| European Union | CHMP negative opinion June 2024, confirmed on re-examination in September 2024; EU refusal December 2024 [80] | Application withdrawn in 2024 (proposed EU name Izelvay); no authorisation [83] |
| United Kingdom | No MHRA authorisation; NICE discontinued its appraisal on 20 February 2026 [84, 85] | No UK authorisation identified at the cutoff |
| Australia | TGA registration 29 January 2025, for every-other-month dosing in adults with an intact fovea whose central vision is threatened by lesion growth [85, 86]; PBAC recommended listing in November 2025, but the sponsor did not proceed [81] | TGA registration 13 October 2025 [87]; PBAC recommended restricted listing in March 2026; not listed at the cutoff [82] |
| Japan | No authorisation identified; the sponsor reported approval only in the United States and Australia in its FY2025 annual report [85] | Conditional approval announced 19 September 2025 (company-reported) [88] |
| China | No authorisation identified [85] | New drug application accepted for priority review in May 2026; not an approval [89] |
Why the conclusions differ. The FDA accepted reduced lesion growth together with product-specific safety provisions. The CHMP judged the clinical relevance of the structural change insufficiently established for the Syfovre application. Australian registration and PBAC recommendations illustrate a further separation between authorisation and publicly subsidised access. These bodies have different statutory mandates, decided at different times and sometimes on different dossiers. Their decisions are therefore an analytical case study, not a natural experiment that identifies one universal threshold of clinical meaningfulness.
8. Clinical safety, red flags and escalation
AMD care needs two distinct urgent pathways: one for new symptoms suggesting active macular neovascularisation, and one for complications after an injection or implant procedure. A new central scotoma, sudden distortion or unexplained deterioration warrants urgent referral to a macula service: within one working day under NICE guidance in the United Kingdom, with treatment, where indicated, within 14 days of referral. [1, 2]
Severe pain, rapidly worsening vision, marked redness or photophobia, a curtain or shadow, or new field loss after a procedure warrants same-day ophthalmic assessment. Possible causes include endophthalmitis, intraocular inflammation, retinal detachment, haemorrhage and vascular occlusion. Missed treatment appointments with new symptoms or suspected activity also warrant rapid contact with the macula service. [1, 7, 8]
Product-specific safety. Pegcetacoplan carries labelled warnings for retinal vasculitis and/or vascular occlusion and for neovascular conversion. Brolucizumab is associated with intraocular inflammation and occlusive retinal vasculitis. In June 2026, the EMA’s Pharmacovigilance Risk Assessment Committee concluded that retinal vasculitis, with or without occlusion, is a possible adverse reaction to ranibizumab, of unknown frequency, and asked for product information to be updated; it did not conclude that the benefit–risk balance had changed. These signals differ in mechanism, frequency and certainty and should not be pooled across products. Implanted delivery systems add operative and device risks. [8, 42, 43, 50, 90]
| Presentation | Typical response | Reason for urgency |
|---|---|---|
| New distortion, central scotoma or abrupt central blur | Urgent referral to a macula service through the local pathway (UK: referral within one working day) | Possible new nAMD activity [2] |
| Severe pain, red eye or worsening vision after an injection | Same-day specialist or emergency ophthalmic review | Endophthalmitis or inflammation [7, 8] |
| New field shadow or rapid loss after a procedure | Same-day emergency ophthalmic review | Detachment, haemorrhage or vascular event [1] |
| Missed nAMD follow-up, new fluid or unexplained acuity loss | Expedited OCT-led review | Prevent prolonged untreated activity [4] |
This table supports professional judgement and local emergency pathways; it does not replace individual triage or product labelling.
9. Living with AMD: function, rehabilitation and dignity
Central visual impairment can compromise reading, face recognition, communication, shopping, driving and medication management. Its effects depend on residual function, fellow-eye vision, contrast, lighting, social resources and the accessibility of the environment. Systematic reviews and cohorts associate AMD with falls, anxiety, depression and reduced quality of life. In a Korean national cohort, AMD with related visual disability was associated with a higher subsequent risk of depression. These are associations; they do not show that any treatment regimen prevents falls or depression. [91–95]
Families often provide transport, appointment support, medication help, reading and navigation. In a German survey of 150 informal caregivers of people with nAMD, mean caregiving time was 6.4 hours a week, with wide variation (standard deviation 8.5 hours). A single caregiver-hours multiplier would therefore mislead. [96]
Rehabilitation is active care. It includes optimised refraction and lighting, contrast enhancement, magnification, digital accessibility tools, eccentric-viewing training, orientation and mobility support, occupational help, and advice on benefits and certification. Clinical teams should ask about mood, falls and driving under local rules. Charles Bonnet syndrome, in which people with visual impairment see vivid images that are not there, deserves a reassuring explanation and appropriate assessment, not a psychiatric label. A 2020 Cochrane review found certainty varying by intervention and outcome: evidence of small benefits to vision-related quality of life was of moderate certainty for methods of enhancing vision, and of low to very low certainty for other comparisons and for general health-related quality of life. [2, 10]
9.1 The Vision Dividend: a measurable research proposition
The Vision Dividend, introduced in the first edition of this article, describes value beyond retinal images: maintained reading and social participation, preserved productive capacity, less caregiver demand and greater ability to manage one’s own health. It is a research proposition, not an established multiplier. Global studies document large productivity losses from visual impairment, but they cover all causes and cannot be converted into a return on investment for AMD treatment without disease-specific causal evidence. [18, 19, 97]
Operationally, the Vision Dividend is defined here as the difference, per treated patient-year, in patient-valued function, caregiver hours and productive time between two fully specified care strategies, measured prospectively with adjustment for age, comorbidity and baseline vision. Sight matters because of what it lets people do, not because a monetary multiplier has been proven.
A complementary health-economics perspective, The Scotoma in the Spreadsheet, examines when effects of eye care may fall outside the budget that pays for it and how such claims can be tested rather than presumed.
10. AI, home OCT and accountable digital retina care
AI tools can detect intraretinal and subretinal fluid, quantify atrophy and photoreceptor loss, estimate risk of progression, prioritise referrals and support remote monitoring. A deep-learning system matched expert retina specialists in referral recommendations from OCT in a research setting, and another predicted conversion to nAMD within six months in the fellow eye. High discrimination on retrospective images does not by itself establish safe deployment, sustained visual benefit or equitable performance. Performance must be shown across devices, ethnic groups, image quality, comorbid phenotypes and clinical settings. [98–100]
The difference between a technically capable diagnostic tool and a completed patient-care pathway is explored in The Eye Clinic of the Future: AI in Ophthalmology and Better Healthcare Systems.
The FDA’s May 2024 De Novo decision for Notal Vision’s home OCT system concerns a specified device and intended use in diagnosed nAMD; it is not permission for autonomous algorithms to prescribe treatment. A prospective trial published in 2024 showed that home OCT-guided management of treatment-experienced nAMD is feasible. By the cutoff, the author identified no published randomised trial showing that AI-guided triage or home monitoring improves visual outcomes in AMD compared with usual care. A safe home-monitoring pathway still needs human review, failure-response protocols, explicit escalation thresholds and equitable provision for people with limited digital access. [31, 32]
Reporting standards apply at different stages: SPIRIT-AI and CONSORT-AI for trial protocols and reports of AI interventions, TRIPOD+AI for prediction models, and DECIDE-AI for early clinical evaluation of decision-support systems. WHO’s 2021 guidance sets out principles of safety, transparency, accountability, inclusiveness and data protection. None of these establishes clinical efficacy or regulatory clearance. [100–104]
For the institutional responsibilities surrounding such tools, see the companion analysis Healthcare AI Governance: Institutional Leadership and Patient-Centred Accountability.
| Stage | Key question | Minimum credible demonstration |
|---|---|---|
| Technical | Is the model reproducible on its intended inputs? | External accuracy, calibration, subgroup and failure analyses |
| Clinical workflow | Can a team act safely on the outputs? | Prospective evaluation, oversight, documented escalation and false-negative review |
| Patient outcome | Does it improve care? | Timeliness, safety, function, retention and equitable access compared with usual practice |
| Health-system value | Is capacity actually released? | Measured time and resources, accessibility, maintenance cost and monitoring |
A safely deployable digital pathway is a clinical service intervention, not merely a high-performing classifier.
11. Economics, equity and real-world capacity
nAMD treatment differs from one-off procedures: effective care means repeated visits, imaging and injections, often for years. Drug acquisition is only one cost. Aseptic preparation, OCT, staff time, injection rooms, safety procedures, transport, waiting time and rehabilitation all shape total cost and patient experience. CATT and IVAN established comparable efficacy for bevacizumab under trial conditions; whether repackaged bevacizumab, biosimilars or originator products save money in practice depends on local procurement, reimbursement and governance. [35, 37, 59, 60]
Operational access, follow-up gaps and accountability can also be examined through the five-domain framework in Reading Health-System Performance Through Eye Care.
Four trade-offs are easily missed:
- Formulary-driven switching between agents can disrupt continuity, confidence and adherence even when the agents are clinically similar.
- Repackaged bevacizumab depends on aseptic compounding, so supply governance is part of the price.
- Longer intervals can delay detection of reactivation in patients who miss visits or are lost to follow-up.
- New GA pathways can displace nAMD capacity in the same injection clinic (Section 13).
Workforce. Capacity is unevenly distributed. A global survey estimated about 3.7 ophthalmologists per million people in low-income countries against 76.2 in high-income countries. Updated estimates for 2023 describe continuing disparities across ophthalmologists, optometrists and allied eye-care staff. The datasets use different years and definitions and should not be combined into a single time series. Imaging-device distribution, trained injection staff, nurses, transport and insurance can limit care as much as ophthalmologist numbers. [105, 106]
The Implementation Chasm. This term, introduced in the first edition of this article, describes the gap between efficacy under a trial schedule and benefit delivered in ordinary health systems. The AURA and SEVEN-UP data in Section 6.4 measure it. The idea draws on established work: the Institute of Medicine’s Crossing the Quality Chasm, the know–do gap, the determinants of the Consolidated Framework for Implementation Research (CFIR) and the reach and maintenance dimensions of RE-AIM. Its specific use in AMD is to locate which patient, visit, equipment, financing or governance step prevents effective treatment from reaching the intended population. [47, 48, 107–109]
Value requires a defined decision problem. An economic evaluation should state its perspective (health system, payer, patient or society), time horizon, disease stage, comparator, regional prices, adverse events, and quality-adjusted life-years alongside functional outcomes where valid. Claims about fewer falls, maintained employment or reduced caregiver burden need causal data; associations between AMD or visual impairment and those outcomes do not show the effect of an intervention. [96, 97, 110]
Equity is more than equal eligibility on paper. It depends on access to diagnosis, safe injections, sustained follow-up, rehabilitation, travel support, affordable devices and culturally appropriate communication. Services should break down missed treatment and retention by geography, deprivation and disability, including in Middle Eastern and low-resource systems where local data remain sparse. [19, 111]
12. The Sustainable Vision Care Framework: a proposed operational synthesis
The framework organises AMD care into four care-pathway functions: (1) prevention and risk reduction, (2) timely detection and accurate classification, (3) effective, equitable treatment and monitoring, and (4) rehabilitation and patient-valued function. These are supported by two enabling capacities: (5) workforce and pathway capacity, and (6) responsible technology and data. All six rest on two cross-cutting foundations: financing and demonstrable value, and governance and service resilience.
An author-proposed synthesis · four care-pathway functions, two enabling capacities and two cross-cutting foundations.
Analytical lenses: Longevity–Vision Paradox (why demand rises) · Structure–Function Challenge (which benefit matters) · Implementation Chasm (why proven benefit fails to reach people). The framework has not been externally validated.
The framework is a descriptive and operational synthesis. Its pillars overlap with WHO’s health-system building blocks and integrated people-centred eye care, the Lancet Commission’s effective-coverage agenda, implementation science and value-based care, and are not claimed as new in themselves. Its candidate contribution is narrower: a disease-specific chain that links the evidence rung a treatment has reached (Section 7.6) to treatment intensity, to staff and room hours (Section 13), and finally to delivered outcomes. Neither the novelty nor the usefulness of that chain has yet been tested externally. [19, 108–112]
Its emphasis on pathways and organisational accountability connects to Integrated Care Is Strategy: The Executive Operating Model for High-Performance Health Systems, which examines integration beyond ophthalmology.
| Pillar or foundation | Indicator | Numerator / denominator | Data source and caution |
|---|---|---|---|
| Prevention | Stage-appropriate AREDS2 counselling | Eligible patients with documented counselling / patients with intermediate AMD or unilateral late AMD | Clinic records; counselling is not behaviour change |
| Detection | Referral-to-assessment time | Suspected nAMD assessed within the local standard / all suspected nAMD referrals | Referral clocks; use the local urgency standard |
| Treatment | Diagnosis-to-first-injection time; overdue fraction | Injections delivered later than a locally set threshold (for example, 2 weeks) / injections due | EHR and booking data; adjust for case mix |
| Treatment outcome | Vision maintained at 12 months | Eyes losing <15 letters at 12 months / treated eyes | Registry or EHR; report loss to follow-up |
| Rehabilitation | Timely low-vision referral | Eligible patients referred within 3 months / eligible patients | Referral logs; outcomes matter more than referral |
| Workforce and capacity | Capacity gap by staff group and room | Required hours − effective hours (Section 13) | Rosters and utilisation; avoid double counting |
| Technology and data | False-negative escalations | Missed active disease found on human review / AI-negative cases audited | Prospective audit; report equity gaps |
| Financing and governance | Cost per effectively treated patient-year; recovery after disruption | Total pathway cost / patient-years in control; weeks to clear backlog after disruption | Payer and governance data; prices are jurisdictional |
How the framework could be evaluated. Three tests are proposed:
- Content validity: a Delphi exercise with retina specialists, nurses, commissioners and patients to refine the indicators.
- Measurement reliability: whether the indicators can be measured consistently across sites from routine data.
- Predictive and implementation utility: for example, whether a higher overdue fraction predicts greater 12-month acuity loss, and whether acting on the indicators reduces it.
If the third test fails, the framework should be revised rather than defended.
Supporting lenses. Three named lenses frame the analysis. The Longevity–Vision Paradox explains why demand rises. The Structure–Function Challenge asks which benefit matters. The Implementation Chasm asks why proven benefit fails to reach people. The Vision Dividend is a measurable hypothesis within the financing foundation, and Workforce Mathematics is a planning tool within the capacity pillar.
13. Workforce mathematics: transparent capacity planning
The model converts patients, follow-up intensity and professional time into a reproducible workload calculation. For each care pathway k and staff group j:
Required annual hours: Hreq,j = Σk (Nk × vk × tk,j) / 60
Effective available hours: Heff,j = Fj × hj × (1 − aj) × (1 − cj)
Here N is the number of patients in the pathway, v the annual visits per patient, t the staff group’s minutes per visit, F whole-time-equivalent staff, h contracted annual hours per whole-time equivalent, a the absence fraction and c the share of time spent on non-clinical work. The difference Hreq,j − Heff,j identifies staff-specific gaps.
The same structure applies to rooms and devices: required injection-room minutes or OCT-device minutes per year (patients × visits × minutes per visit) can be compared with available minutes after maintenance and downtime. Whichever resource has the largest relative deficit is the binding constraint. Non-attendance is a separate constraint, not a second deduction from capacity: an unfilled slot wastes time only if it is not reused.
Worked example (fictional; not a prediction for any real service). A centre follows 200 nAMD patients with seven injection visits a year. At 25 nursing minutes per visit, nAMD demand is 200 × 7 × 25 / 60 = 583.3 hours. Opening a pathway for 60 GA patients at an illustrative ten treatment visits a year adds 60 × 10 × 25 / 60 = 250.0 hours. Total nursing demand is 833.3 hours. If 700.0 effective hours are available, the deficit is 133.3 hours before any allowance for variability. The GA pathway also adds 600 injection appointments and further imaging. Ten visits a year is a modelling assumption within the range of current US labels (pegcetacoplan every 25–60 days; avacincaptad pegol monthly), not a recommendation.
A different resource may bind first. If 2,000 procedure slots are needed but only 1,800 exist, the 200-slot shortfall remains even with enough staff hours. Capacity also needs a buffer below theoretical maximum: unpredictable referrals, rescheduling, complications and variation in demand create backlog even when average demand equals average capacity. With Dt appointments falling due, St delivered and Bt already overdue, the next period’s backlog is Bt+1 = max(0, Bt + Dt − St), provided that rescheduled patients are not double-counted.
| Minutes per visit | 6 visits/year | 7 visits/year | 8 visits/year |
|---|---|---|---|
| 20 | 200.0 | 233.3 | 266.7 |
| 25 | 250.0 | 291.7 | 333.3 |
| 30 | 300.0 | 350.0 | 400.0 |
These are checkable arithmetic, not estimates of any provider’s needs. The model becomes a decision tool only when local arrival patterns, case mix, task times, backfilling and patient outcomes are measured prospectively.
A related but distinct continuity-of-care measurement proposal, The Care Recovery Clock, considers how restored service capacity and verified patient-care recovery can diverge after disruption.
14. Adapting care across regions and health systems
No single AMD delivery model suits every setting. High-capacity centres may refine treatment intervals and AI-assisted monitoring; resource-limited networks may first need reliable symptom recognition, transport to referral, an OCT access point, sterile injection capability and treatment continuity. Priorities should follow the measured weakest point in each pathway rather than an assumption that the newest innovation is the most urgent need.
Evidence from high-income Western centres may not represent the case mix of East Asia, the Middle East or underserved populations. PCV is more frequent among people of Asian ancestry with nAMD, and diagnostic pathways should reflect this. Where ICGA is unavailable, OCT-based PCV criteria and explicit referral routes for recurrent haemorrhage or poor response are safer than assuming uniform technology. Regional prevalence or PCV proportions should be quoted only after their sampling frame, imaging method, age standardisation and denominators have been checked. [24–26, 62]
The Gulf and wider Middle East illustrate the point. Highly specialised retinal centres can coexist with uneven access, variable insurance cover and migrant populations facing distinct barriers. Published data on referral delay, stage at presentation, treatment interruption, patient costs and rural–urban outcomes are sparse. Measuring them is a priority, and findings from one Gulf health system should not be generalised to others.
Across the life course, related condition-specific analyses address retinopathy of prematurity and neonatal screening governance, amblyopia and childhood vision-care pathways, and diabetic retinopathy screening and treatment access. Their clinical requirements differ from AMD, but the shared delivery questions include referral completion, continuity and equitable access.
Where equipment or workforce is constrained, options include shared referral criteria, triage rules with clinical oversight, supported travel, transparent biosimilar procurement where lawful, validated remote image review and low-vision provision. Resilience means maintaining injection and assessment continuity through holidays, epidemics, supply shortages and staff absence, not merely owning digital infrastructure. [19, 106, 111]
The population-measurement distinction between service activity and true disease burden is explored in Amblyopia and the Public Health Data Gap, an additional example of why recorded throughput is not itself a population outcome.
15. Research priorities to 2030
- Do nAMD pathways achieve shorter referral-to-treatment times and fewer missed visits, measured in service-level referral, injection and acuity records?
- Do durable nAMD therapies reduce actual visits, not only injections, without worse vision or safety at 12–24 months?
- Do GA treatments improve patient-valued function in prospectively designed trials such as ARCHER II and in pragmatically selected populations?
- Does home imaging or AI improve timeliness, equity or efficiency compared with usual care in prospective, preferably randomised, evaluation?
- Do validated capacity models reduce overdue-appointment backlog without shifting risk or burden to patients?
- How do biosimilar and low-cost-therapy policies affect total cost, outcomes and equity?
- Does systematic rehabilitation referral improve patient-reported daily activity, wellbeing and participation across health systems?
Future editions will report whether each question was answered, contradicted or remains open. Sponsor projections are not probabilities of success.
16. Implications and recommendations
- Clinical leaders: use evidence-based staging, urgent pathways for new nAMD symptoms, timely OCT-led injection care, product-specific safety counselling and consistent recording of long-term outcomes. Protect treatment continuity and refer actively for rehabilitation. [1, 2, 4]
- Public-health leaders: build retinal health into healthy-ageing programmes, prioritise tobacco control and access, and report burden by disease stage, visual impairment, socioeconomic context and geography rather than headline counts. [11, 12, 18, 19]
- Commissioners and executives: measure effective capacity by staff group and room, compare drug options on whole-pathway value and safety, track overdue appointments and loss to follow-up, and fund recovery plans for predictable disruption.
- Technology evaluators: require external validation, prospective impact data, failure-escalation plans, privacy safeguards and subgroup analysis before scaling AI or home monitoring. A device authorisation is not authorisation for autonomous AMD management. [31, 99]
- Patients and families: ask about disease stage, likely outcomes, injection burden, warning symptoms, fellow-eye risk, costs, support services and how to protect the daily activities that matter most to you.
| Recommendation | Evidence basis | Evidence certainty | Editorial strength |
|---|---|---|---|
| Maintain an urgent suspected-nAMD pathway and timely anti-VEGF treatment [2, 4, 33, 34] | Guidelines and multiple RCTs | High for anti-VEGF efficacy; setting-specific for access metrics | Strong |
| Use OCT-led treat-and-extend retreatment and record intervals, activity and overdue visits [4, 45, 46] | Guideline and RCTs | Moderate to high | Strong |
| Offer smoking cessation, stage-appropriate AREDS2 counselling and symptom advice [3, 27, 28] | RCTs in eligible stages; strong prevention evidence for smoking | Moderate to high for eligible stages; no benefit shown in early AMD | Strong, with eligibility |
| Discuss GA therapy in terms of structural effect, functional uncertainty, safety, access and preferences [5–8] | RCTs, extensions, regulator decisions, observational data | High for anatomical effect; not demonstrated for prespecified function | Shared decision-making |
| Integrate low-vision support and household needs into AMD pathways [10, 96] | Trials, systematic reviews, observational studies | Low to moderate, by outcome | Strong, as an access goal |
| Pilot capacity and equity measurement before large-scale change [106, 111] | Implementation principles; proposed model | Not yet prospectively validated | Conditional: pilot and evaluate |
| Validate AI and home OCT prospectively, with safety escalation [32, 98, 99, 104] | Technical studies, feasibility trials, device regulation | Low for patient outcomes | Strong governance requirement |
Final reflection. Evidence has changed the outlook for people living with AMD, yet a scientific gain becomes a lasting human benefit only when it survives the journey from trial endpoint to everyday function and consistent access. Retinal lesions are measured in square millimetres; their consequences are lived in reading, relationships, work and independence. A sustainable vision-care system should be judged at all three levels: anatomical effect, patient-valued outcome and equitable delivery.
For the wider collection linking these retina, public-health and healthcare-management perspectives, visit the author’s Publications and Research archive.
Limitations, declarations and citation
Limitations. This is a purposive narrative synthesis, without dual independent screening or formal risk-of-bias assessment. Regulatory and reimbursement details are current only to 23 October 2026. Observational evidence is vulnerable to selection and confounding, and differences between trials do not establish head-to-head superiority. Several October 2026 developments are reported from company or conference disclosures and may change on full publication. The framework, its indicators and the capacity model are author-proposed and await empirical testing. None of these limitations weakens the established efficacy of anti-VEGF therapy in nAMD.
Originality and attribution. The Longevity–Vision Paradox, Structure–Function Challenge, Implementation Chasm, Vision Dividend and Sustainable Vision Care Framework are the author’s analytical synthesis, first published on this website on 23 June 2026. They build on established work in public health, surrogate-endpoint methodology, implementation science and integrated eye care, which is cited where relevant, and make no claim to external validation.
Competing interests and funding. The author declares no competing interests and received no external funding for this work.
Use of AI tools. AI tools assisted with language editing, evidence organisation and source checking. The author is responsible for the scientific interpretation, citation decisions and all content.
Clinical note. This educational article is not individual medical advice, a clinical practice guideline or an endorsement of investigational treatment. Clinicians and patients should consult current national prescribing information and specialist advice.
Version history. Version 1.0, first published 23 June 2026. Version 1.1, revised 25 July 2026. Version 2.5 (second edition), October 2026: full revision with evidence reviewed to 23 October 2026. Versions 2.0–2.4 were unpublished review drafts.
Suggested citation. Al-Diri S. Age-Related Macular Degeneration: Population Ageing, Health-System Impact, Artificial Intelligence, and the Future of Sustainable Vision Care — Preserving Sight in an Ageing World. 2nd ed. (Version 2.5). DrSamerAlDiri.com; 2026. First published 23 June 2026. Available at: https://drsameraldiri.com/age-related-macular-degeneration-population-ageing-health-system-impact-artificial-intelligence-and-the-future-of-sustainable-vision-care/
Open access and copyright. © 2026 Dr. Samer Al-Diri. This article is freely available to read, download and share in its original, unmodified form for non-commercial purposes, provided that the author is credited and the original article and licence are linked. It is published under the Creative Commons Attribution–NonCommercial–NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Commercial use or distribution of adaptations or translations requires the author’s prior permission. Any separately credited third-party material remains subject to its own rights.
References
- Vemulakonda GA, Bailey ST, Kim SJ, et al. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology. 2025;132(4):P1–P74. doi:10.1016/j.ophtha.2024.12.018
- National Institute for Health and Care Excellence. Age-related macular degeneration. NICE guideline NG82; 2018 (current online guidance). https://www.nice.org.uk/guidance/ng82/chapter/recommendations
- National Eye Institute. AREDS/AREDS2 nutritional supplements for age-related macular degeneration. Patient guidance, accessed October 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/nutritional-supplements-age-related-macular-degeneration
- Loewenstein A, Zinkernagel MS, Schlingemann RO, et al. Updated guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Ophthalmologica. Published online 12 October 2026. doi:10.1159/oph/aeeag010
- Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434–1448. doi:10.1016/S0140-6736(23)01520-9
- Khanani AM, Danzig CJ, Heier JS, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial. Ophthalmology. 2026;133(4):451–465. doi:10.1016/j.ophtha.2025.12.011
- US Food and Drug Administration. IZERVAY (avacincaptad pegol intravitreal solution) prescribing information, revised February 2026 (NDA 217225, supplement 004); current label on DailyMed. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf
- US National Library of Medicine, DailyMed. SYFOVRE (pegcetacoplan injection) prescribing information: indication, dosing every 25–60 days, and retinal vasculitis/retinal vascular occlusion warning. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4434e61-9ec9-4e0e-bd60-45aaa0a87e64
- Keenan TDL, Hébert M, Chew EY, Johnson MW. What should patients with age-related macular degeneration eat? Am J Ophthalmol. 2026;288:12–21. doi:10.1016/j.ajo.2026.04.003
- van Nispen RMA, Virgili G, Hoeben M, et al. Low vision rehabilitation for better quality of life in visually impaired adults. Cochrane Database Syst Rev. 2020;1:CD006543. doi:10.1002/14651858.CD006543.pub2
- Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
- GBD 2021 Global AMD Collaborators. Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Glob Health. 2025;13(7):e1175–e1190. doi:10.1016/S2214-109X(25)00143-3
- Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844–851. doi:10.1016/j.ophtha.2012.10.036
- Gruenberg EM. The failures of success. Milbank Mem Fund Q Health Soc. 1977;55(1):3–24. doi:10.2307/3349592
- Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303(3):130–135. doi:10.1056/NEJM198007173030304
- World Health Organization. World report on ageing and health. Geneva: WHO; 2015. https://www.who.int/publications/i/item/9789241565042
- Beard JR, Officer A, de Carvalho IA, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145–2154. doi:10.1016/S0140-6736(15)00516-4
- World Health Organization. World report on vision. Geneva: WHO; 2019. https://www.who.int/publications/i/item/9789241516570
- Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489–e551. doi:10.1016/S2214-109X(20)30488-5
- Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123(11):1570–1574. doi:10.1001/archopht.123.11.1570
- Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125(4):537–548. doi:10.1016/j.ophtha.2017.09.028
- Guymer RH, Rosenfeld PJ, Curcio CA, et al. Incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology. 2020;127(3):394–409. doi:10.1016/j.ophtha.2019.09.035
- Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127(5):616–636. doi:10.1016/j.ophtha.2019.11.004
- Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708–724. doi:10.1016/j.ophtha.2017.11.019
- Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935–942. doi:10.1001/jamaophthalmol.2020.2443
- Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443–452. doi:10.1016/j.ophtha.2020.08.006
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. doi:10.1001/archopht.119.10.1417
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–2015. doi:10.1001/jama.2013.4997
- Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140(7):692–698. doi:10.1001/jamaophthalmol.2022.1640
- Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial. Ophthalmology. 2019;126(6):829–838. doi:10.1016/j.ophtha.2018.09.015
- US Food and Drug Administration. Notal Vision Home OCT System: De Novo decision DEN230043, 15 May 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN230043
- Holekamp NM, de Beus AM, Clark WL, Heier JS. Prospective trial of home optical coherence tomography-guided management of treatment-experienced neovascular age-related macular degeneration patients. Retina. 2024;44(10):1714–1731. doi:10.1097/IAE.0000000000004167
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
- CATT Research Group; Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
- Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
- Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi:10.1016/S0140-6736(22)00010-1
- Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141–1152. doi:10.1016/S0140-6736(24)00063-1
- American Journal of Managed Care. FDA delivers complete response letter for longer dosage intervals of aflibercept 8 mg in DME and wet AMD. 21 April 2025. https://www.ajmc.com/view/fda-delivers-crl-for-longer-dosage-intervals-in-aflibercept-for-dme-wet-amd
- Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
- European Medicines Agency. Beovu (brolucizumab): European public assessment report and product information, including warnings on intraocular inflammation, retinal vasculitis and retinal vascular occlusion. https://www.ema.europa.eu/en/medicines/human/EPAR/beovu
- Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295–307. doi:10.1016/j.ophtha.2021.09.016
- Kertes PJ, Galic IJ, Greve M, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol. 2020;138(3):244–250. doi:10.1001/jamaophthalmol.2019.5540
- Guymer RH, Markey CM, McAllister IL, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126(5):723–734. doi:10.1016/j.ophtha.2018.11.025
- Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
- Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
- Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
- European Medicines Agency. Susvimo (ranibizumab): European public assessment report; EU marketing authorisation 18 September 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/susvimo
- Roche Registration GmbH. Withdrawal of the marketing authorisation application for Susvimo (ranibizumab): letter to the European Medicines Agency, 2 May 2023. https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-susvimo_en.pdf
- Ophthalmology Times. Genentech receives FDA approval to relaunch Susvimo: report of the October 2022 voluntary recall for septum dislodgement and the US reintroduction. 8 July 2024. https://www.ophthalmologytimes.com/view/genentech-receives-fda-approval-to-relaunch-susvimo
- Retinal Physician. DAYBREAK meets primary endpoint in wet AMD: report of the Kodiak Sciences release on Zenkuda (tarcocimab tedromer) and tabirafusp tedromer, 28 September 2026. https://retinalphysician.com/news/2026/daybreak-meets-primary-endpoint-in-wet-amd/
- Ophthalmology Times. AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD. Conference report, 9 October 2026. https://www.ophthalmologytimes.com/view/aao-2026-daybreak-shows-tarcocimab-and-tabirafusp-ted-noninferior-to-aflibercept-in-wet-amd
- Ocular Therapeutix, Inc. Quarterly report (Form 10-Q) for the period ended 30 June 2026, including SOL-1 results. US Securities and Exchange Commission filing. https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm
- EyePoint Pharmaceuticals. Topline results of the LUGANO and LUCIA phase 3 trials of Duravyu in wet AMD, 19 October 2026. SEC filing, exhibit 99.1. https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm
- Opthea Limited. ShORe phase 3 trial of sozinibercept in wet AMD did not meet its primary endpoint; COAST previously reported. Press release, 31 March 2025 (SEC exhibit 99.1). https://www.sec.gov/Archives/edgar/data/0001815620/000095017025047169/opt-ex99_1.htm
- REGENXBIO Inc. Second quarter 2026 financial results and operational highlights: surabgene lomparvovec (ABBV-RGX-314) pivotal programme. Company release, August 2026. https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-second-quarter-2026-financial-results-and
- European Medicines Agency. Lytenava (bevacizumab gamma): European public assessment report; EU marketing authorisation 27 May 2024 for neovascular AMD. https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava
- European Medicines Agency. Biosimilar medicines: overview, and European public assessment reports for authorised ranibizumab and aflibercept biosimilars. https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview
- Managed Healthcare Executive. Yesafili, an Eylea biosimilar, launches in the United States. 3 August 2026. https://www.managedhealthcareexecutive.com/view/yesafili-an-eylea-biosimilar-launches-with-a-price-of-1-445
- Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–793. doi:10.1001/jamaophthalmol.2018.1804
- Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666–677. doi:10.1001/jamaophthalmol.2018.1544
- Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186–195. doi:10.1016/j.ophtha.2019.07.011
- Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128(4):576–586. doi:10.1016/j.ophtha.2020.08.027
- Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402(10411):1449–1458. doi:10.1016/S0140-6736(23)01583-0
- Wykoff CC, Holz FG, Chiang A, et al. Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE. Am J Ophthalmol. 2025;276:350–364. doi:10.1016/j.ajo.2025.04.016
- Shen M, Lam WZ, Berni A, et al. Two-year experience with intravitreal pegcetacoplan for the treatment of geographic atrophy in clinical practice. Am J Ophthalmol. Published online 11 September 2026. doi:10.1016/j.ajo.2026.09.011
- Retina Today. Three years after pegcetacoplan approval (sponsored supplement, September 2026), citing Apellis post-marketing data on file for retinal vasculitis reporting rates. https://retinatoday.com/issues/2026-sept-supplement
- Kailani Z, Mihalache A, Popovic MM, Kertes PJ, Muni RH. Ocular adverse events associated with pegcetacoplan and avacincaptad pegol for geographic atrophy: a population-based pharmacovigilance study. Am J Ophthalmol. 2025;276:252–260. doi:10.1016/j.ajo.2025.04.022
- US Food and Drug Administration. Valeda Light Delivery System: De Novo decision DEN230083, 4 November 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN230083
- Boyer D, Hu A, Warrow D, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda Light Delivery System. Retina. 2024;44(3):487–497. doi:10.1097/IAE.0000000000003980
- Holz FG, Le Mer Y, Muqit MMK, et al. Subretinal photovoltaic implant to restore vision in geographic atrophy due to AMD. N Engl J Med. 2026;394(3):232–242. doi:10.1056/NEJMoa2501396
- Science Corporation. PRIMA receives CE marking under the EU Medical Device Regulation. Manufacturer announcement, 22 July 2026. https://science.xyz/news/ce-mark/
- Annexon Biosciences. Annexon expands vonaprument phase 3 programme in geographic atrophy with addition of a month-24 dual primary endpoint. Company release, 12 August 2026. https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy
- Annexon Biosciences. Annexon to present patient baseline characteristics from the vonaprument phase 3 ARCHER II pivotal trial. Company release, 24 September 2026. https://www.globenewswire.com/news-release/2026/09/24/3368269/0/en/annexon-to-present-patient-baseline-characteristics-from-vonaprument-phase-3-archer-ii-pivotal-trial-for-geographic-atrophy-at-the-retina-society-59th-annual-scientific-meeting.html
- Belite Bio. Unaudited second quarter 2026 financial results and corporate update: PHOENIX phase 3 trial of tinlarebant in geographic atrophy. Company release, 13 August 2026. https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial
- Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–613. doi:10.7326/0003-4819-125-7-199610010-00011
- Glance (Eyes On Eyecare). Real-world pegcetacoplan data show visual acuity benefits through 18 months. Report of an ASRS 2026 presentation, 20 July 2026. https://glance.eyesoneyecare.com/stories/2026-07-20/real-world-pegcetacoplan-data-shows-va-benefits-through-18-months/
- European Medicines Agency. Syfovre (pegcetacoplan): refusal of marketing authorisation; CHMP opinion and re-examination, 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre
- Pharmaceutical Benefits Advisory Committee (Australia). Pegcetacoplan: Public Summary Document, November 2025 meeting. https://prod3.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3
- Pharmaceutical Benefits Scheme (Australia). Avacincaptad pegol: medicine status and PBAC outcome, March 2026. https://prod2.pbs.gov.au/medicinestatus/document/1499
- European Medicines Agency. Izelvay (avacincaptad pegol): withdrawal of the marketing authorisation application, 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay
- National Institute for Health and Care Excellence. Pegcetacoplan for treating geographic atrophy [ID4041]. Appraisal discontinued 20 February 2026. https://www.nice.org.uk/guidance/discontinued/gid-ta11351
- Apellis Pharmaceuticals, Inc. Annual report (Form 10-K) for fiscal year 2025: SYFOVRE approved in the United States and Australia; TGA indication. US Securities and Exchange Commission filing, 2026. https://www.sec.gov/Archives/edgar/data/1492422/000119312526065179/apls-20251231.htm
- Therapeutic Goods Administration (Australia). SYFOVRE (pegcetacoplan), ARTG 404733; registered 29 January 2025. https://www.tga.gov.au/resources/artg/404733
- Therapeutic Goods Administration (Australia). IZERVAY (avacincaptad pegol), ARTG 447210; registered 13 October 2025. https://www.tga.gov.au/resources/artg/447210
- Astellas Pharma. Conditional approval of IZERVAY in Japan for geographic atrophy secondary to AMD. Press release, 19 September 2025. https://www.astellas.com/en/system/files/news/2025-09/deee5bf20a/20250919_en_1.pdf
- Astellas Pharma. China's NMPA accepts new drug application for IZERVAY for geographic atrophy and grants priority review. Company announcement, 15 May 2026. https://newsroom.astellas.com/2026-05-15-chinas-nmpa-accepts-ndapplication-for-izervay-for-the-treatment-of-geographic-atrophy-secondary-to-age-related-macular-degeneration
- European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Periodic safety update single assessment PSUSA/00002609/202510 for ranibizumab: retinal vasculitis with or without occlusion (frequency not known), June 2026; product information updated. https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac
- Wood JM, Lacherez P, Black AA, et al. Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(8):5088–5092. doi:10.1167/iovs.10-6644
- Dawson SR, Mallen CD, Gouldstone MB, Yarham R, Mansell G. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol. 2014;14:78. doi:10.1186/1471-2415-14-78
- Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6(12):e011504. doi:10.1136/bmjopen-2016-011504
- Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. Br J Ophthalmol. 2006;90(5):593–596. doi:10.1136/bjo.2005.086595
- Hwang S, Kang SW, Kim SJ, et al. Impact of age-related macular degeneration and related visual disability on the risk of depression: a nationwide cohort study. Ophthalmology. 2023;130(6):615–623. doi:10.1016/j.ophtha.2023.01.014
- Weyer-Wendl H, Walter P. Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration. Health Econ Rev. 2016;6:37. doi:10.1186/s13561-016-0116-4
- Marques AP, Ramke J, Cairns J, et al. Global economic productivity losses from vision impairment and blindness. EClinicalMedicine. 2021;35:100852. doi:10.1016/j.eclinm.2021.100852
- De Fauw J, Ledsam JR, Romera-Paredes B, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24(9):1342–1350. doi:10.1038/s41591-018-0107-6
- Yim J, Chopra R, Spitz T, et al. Predicting conversion to wet age-related macular degeneration using deep learning. Nat Med. 2020;26(6):892–899. doi:10.1038/s41591-020-0867-7
- World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: WHO; 2021. https://www.who.int/publications/i/item/9789240029200
- Cruz Rivera S, Liu X, Chan AW, et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat Med. 2020;26(9):1351–1363. doi:10.1038/s41591-020-1037-7
- Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK; SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat Med. 2020;26(9):1364–1374. doi:10.1038/s41591-020-1034-x
- Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi:10.1136/bmj-2023-078378
- Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med. 2022;28(5):924–933. doi:10.1038/s41591-022-01772-9
- Resnikoff S, Lansingh VC, Washburn L, et al. Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs? Br J Ophthalmol. 2020;104(4):588–592. doi:10.1136/bjophthalmol-2019-314336
- Resnikoff S, Block SS, Chai S, et al. The global eye care workforce: 2023 estimates across ophthalmologists, optometrists, and allied personnel. AJO International. 2026;3:100260. doi:10.1016/j.ajoint.2026.100260
- Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001. doi:10.17226/10027
- Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi:10.1186/1748-5908-4-50
- Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327. doi:10.2105/AJPH.89.9.1322
- Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–2481. doi:10.1056/NEJMp1011024
- World Health Organization. Package of eye care interventions. Geneva: WHO; 2022. https://www.who.int/publications/i/item/9789240048959
- World Health Organization. Everybody's business: strengthening health systems to improve health outcomes. WHO's framework for action. Geneva: WHO; 2007. https://www.who.int/publications-detail-redirect/everybody-s-business—-strengthening-health-systems-to-improve-health-outcomes